2024
Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes
Volovsky M, Seifer D. Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes. Journal Of Clinical Medicine 2024, 13: 3739. PMID: 38999305, PMCID: PMC11242103, DOI: 10.3390/jcm13133739.Peer-Reviewed Original ResearchAssisted reproductive technologyGrowth differentiation factor 9Follicle-stimulating hormoneEndometrial biomarkersAnti-Mullerian hormoneBone morphogenetic protein 15Differentiation factor 9Immune markersOvarian biomarkersART outcomesGene profilesReproductive technologyFactor 9Predicting outcomeBiomarkersCustomized implantsProteomic technologiesHormoneOutcomesClinical integration
2017
Ovarian reserve testing: a user’s guide
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. American Journal Of Obstetrics And Gynecology 2017, 217: 129-140. PMID: 28235465, DOI: 10.1016/j.ajog.2017.02.027.Peer-Reviewed Original ResearchConceptsOvarian reserve testingOvarian reserve testsOvarian reserveAntimüllerian hormoneDay 3 follicle-stimulating hormonePolycystic ovary syndromeFemale cancer patientsFollicle-stimulating hormoneFertility treatment optionsSelection of treatmentAntral follicular countAge-specific valuesGood predictive valueComplex clinical phenomenonOvarian hyperstimulationOvarian stimulationOvary syndromeGonadotoxic therapyTreatment optionsCancer patientsPoor responseReproductive ageFollicular countReproductive endocrinologistsTreatment protocol
2012
High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers
Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, Broekmans F, Baker VL. High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertility And Sterility 2012, 98: 1037-1042. PMID: 22771028, DOI: 10.1016/j.fertnstert.2012.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAnti-Mullerian HormoneChemistry, ClinicalEstradiolFemaleFertilityFollicle Stimulating Hormone, HumanHumansMenstrual CycleMiddle AgedOocytesOvulation InductionPredictive Value of TestsPrognosisReference StandardsReproductive MedicineRetrospective StudiesUnited StatesYoung AdultConceptsYears of ageFSH valuesSerum AMHAntimüllerian hormoneAMH valuesFertility centerCut pointsDay 2Clinical discordanceMenstrual cycle day 2Follicle-stimulating hormone levelsCycle day 2Reference laboratoryFollicle-stimulating hormoneLarger patient populationSingle reference laboratoryFrequency of discordanceAge-dependent fashionClinical cut pointsSame serum samplesOvarian stimulationPatient populationAMH testingMenstrual cycleHormone levels
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
2003
In vitro fertilization in the older patient.
Derman SG, Seifer DB. In vitro fertilization in the older patient. Current Women'S Health Reports 2003, 3: 375-83. PMID: 12959695.Peer-Reviewed Original ResearchConceptsOlder patientsClomiphene citrate challenge testBasal follicle-stimulating hormoneAntral follicle countDiminished ovarian reserveLower oocyte yieldFollicle-stimulating hormoneHigher miscarriage rateMüllerian-inhibiting substanceHigher cancellation rateIVF success ratesLower pregnancy ratesFlare protocolInhibin BIVF patientsMiscarriage rateOvarian reserveOvarian volumeFollicle countGnRH antagonistOocyte yieldEstradiol levelsPregnancy rateAgonist doseStimulation protocol
1999
Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone
Seifer D, Scott R, Bergh P, Abrogast L, Friedman C, Mack C, Danforth D. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertility And Sterility 1999, 72: 63-65. PMID: 10428149, DOI: 10.1016/s0015-0282(99)00193-4.Peer-Reviewed Original ResearchConceptsSerum inhibin B levelsInhibin B levelsDay 3 FSH levelsCycle cancellation rateClinical pregnancy rateSerum inhibin BOvarian reserveFSH levelsB levelsInhibin BPregnancy rateCancellation rateDay 3 follicle-stimulating hormoneDay 3 serum FSH levelsHigher cycle cancellation rateTertiary-care fertility centreNumber of ampulesSerum FSH levelsSerum FSH concentrationsFollicle-stimulating hormoneCase-control studyNumber of oocytesOvarian responsivenessFSH concentrationsGonadotropin requirements
1993
Proliferative index of human luteinized granulosa cells varies as a function of ovarian reserve
Seifer D, Charland C, Berlinsky D, Penzias A, Haning R, Naftolin F, Barker B. Proliferative index of human luteinized granulosa cells varies as a function of ovarian reserve. American Journal Of Obstetrics And Gynecology 1993, 169: 1531-1535. PMID: 8267057, DOI: 10.1016/0002-9378(93)90430-q.Peer-Reviewed Original ResearchConceptsSerum follicle-stimulating hormone levelsFollicle-stimulating hormone levelsFollicle-stimulating hormoneLuteinized granulosa cellsIU/L.Ovarian reserveHormone levelsProliferative indexGranulosa cellsHormone groupChronologic agePreovulatory folliclesDay 3 follicle-stimulating hormone levelsHigh follicle-stimulating hormoneLower follicle-stimulating hormoneSerum follicle-stimulating hormoneFlow cytometryHuman luteinized granulosa cellsGreater proliferative indexSame chronologic ageWoman's ovarian reserveOvulation induction protocolsProspective cohort studyAdvanced reproductive ageIU/L